SecBot SecBot
SECBOTREPLAY Home › Report › EWTX

EWTX · Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46,…

Edgewise Therapeutics, Inc. · 8-K filed May 7, 2026 at 09:20 ET

At the news

NEUTRALIMPACT 4/10

8-K filed May 7, 2026 at 09:20 ET

Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~4.2%. The pre-revenue biotech highlighted positive long-term sevasemten stabilization data and reiterated key catalysts (CIRRUS-HCM 12-week data in Q2 2026, GRAND CANYON pivotal results in Q4 2026). Cash decreased to $499.6M, with R&D spending up YoY as pipeline programs advanced.

  • Net loss per share $0.46 vs consensus $0.48 beat (5.2% surprise)
  • Cash, cash equivalents and marketable securities $499.6M as of March 31, 2026
  • R&D expenses $42.7M (up from $36.8M in Q1 2025) due to increased EDG-7500 and EDG-15400 activity
  • Net loss widened to $49.0M from $40.8M in Q1 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access